Apr 23 |
Evolus to Report First Quarter Financial Results on May 7, 2024
|
Apr 21 |
11 Best Low Price Pharma Stocks To Invest In
|
Apr 17 |
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®
|
Apr 12 |
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Apr 6 |
Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company
|
Mar 26 |
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
Mar 20 |
Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028
|
Mar 17 |
Survey finds GLP-1 users more inclined to get aesthetic procedures
|
Mar 14 |
10 Stocks George Soros and Insiders Are Crazy About
|
Mar 13 |
Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?
|